Financial calendar for 2008 and update on next meetings with analysts and investors
IPH 2201, a novel monoclonal antibody targeting NK cells, enters into regulatory pre-clinical development
Turnover of 5.1 million euros for the first nine months of 2007
Approval from the French authorities to start an exploratory Phase II clinical trial in CML with IPH 1101
Financial results for the first semester of 2007
Number of shares and voting rights, as of July 31, 2007
IPH 2101 (NN 1975), developed in collaboration with Novo Nordisk A/S, was administered for the first time in patients suffering from multiple myeloma
Approval for phase II trial with IPH 1101 in HCV
In-licensing agreement with Cancer Research Technology on novel TLR agent
Updates on next meetings with analysts and investors
